Haven't seen that much switching in the technology base, just in its application. Yes, the pregnancy suspension was a total failure and abandoned. That happens.
Since then their core technology has always been vector delivery of ssDNA. Primary application initially was telomere repair - this is now delayed behind antisense molecule delivery, but it's all built on the same core technology. Incidentally, I totally believe in a significant future for both gene therapy and antisense - they both have their merits.
Other businesses mentioned ie shrimp, regeniderm have all been tactical approaches to near term revenues. Not a bad thing, in fact good if they can be achieved without defocusing the main event.
Yes there's lots of vectors out there, but CYGS claims the only one capable of delivering ssDNA into the cell. Not insignificant in my view. This should be publishable in its own right.
Yes, there's a long road ahead to a cure, but I like early stage biomeds. Lots of opportunity for market cap increase ahead of realizing product revenues. Much less risk than later stage companies in my experience. I prefer this to binary crash or explode action based on the results of a Phase III trial. Alliances do happen. Also the time must be coming for big pharma to take a more active role in both gene therapy and antisense, don't you think. Lots of possibilities in my view.
I agree that if anyone's expecting a killer news item and CYGS going to $100 in the next three months with a cure for cancer, they're delusional. I do expect some solid increases in market cap over time as things unfold, but everyone needs to make up their own mind about that. It's easy, for me personally, to see increases in the current $12M cap on publication, alliances, further science announcements etc. as/when/if they happen.
You and many others don't like this early stage - fine. That's what it's all about, that's why stock prices rise.
Graham |
